The overall goal of the University of Kansas Alzheimer's Disease Core Center (KU ADCC) Neuromaging Core is to enhance the neuroimaging infrastructure and facilitate increased research in aging and Alzheimer's disease for researchers at the University of Kansas and nearby institutions. The Neuroimaging Core builds on the established resources of the (i) KU Hoglund Brain Imaging Center that brings together, in a specialized research building, a unique array of human (3 Tesla) and animal (9.4 Tesla) MRI and cortical (151 channel) and fetal (83 channel) magnetoencephalography (MEG), and the (ii) KU Hospital that provides positron emission tomography as well as a strong faculty of imaging scientists with outstanding experience across the modalities. Accordingly, the Neuroimaging Core is ideally resourced to support current and future investigators who use imaging as a research tool. This goal will be achieved through three specific aims that provide (i) state-of-the-art imaging facilities and professional neuroimaging support, (ii) advanced education in imaging sciences and (iii) novel imaging approaches to AD investigators of the University of Kansas, the state of Kansas, and the Kansas City metropolitan area.
The Specific Aims of the KU ADCC Neuroimaging Core are Aim 1. Provide an integrated imaging environment with advanced scientific support and subsidized scans for AD research Aim 2. Provide advanced training, and education in imaging for ADCC investigators.
Aim 3. Develop novel imaging techniques for studies in AD.
Neuroimaging provides a non-invasive means to measure structure and function of the living human brain. The Neuroimaging Core will support scientists investigating Alzheimer's and other neurodegenerative diseases of aging by providing access to state-of-the-art imaging, education and training in imaging modalities, and novel imaging methods.
|Alosco, Michael L; Duskin, Jonathan; Besser, Lilah M et al. (2017) Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set. J Alzheimers Dis 57:953-968|
|Pandya, Seema Y; Lacritz, Laura H; Weiner, Myron F et al. (2017) Predictors of Reversion from Mild Cognitive Impairment to Normal Cognition. Dement Geriatr Cogn Disord 43:204-214|
|Grill, Joshua D; Apostolova, Liana G; Bullain, Szofia et al. (2017) Communicating mild cognitive impairment diagnoses with and without amyloid imaging. Alzheimers Res Ther 9:35|
|Wilkins, Heather M; Koppel, Scott J; Bothwell, Rebecca et al. (2017) Platelet cytochrome oxidase and citrate synthase activities in APOE ?4 carrier and non-carrier Alzheimer's disease patients. Redox Biol 12:828-832|
|Katsumata, Yuriko; Nelson, Peter T; Ellingson, Sally R et al. (2017) Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. Neurobiol Aging 53:193.e17-193.e25|
|Wilkins, Heather M; Weidling, Ian W; Ji, Yan et al. (2017) Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration. Front Immunol 8:508|
|Fu, Xian; Adams, Zachary; Liu, Rui et al. (2017) Methionine Sulfoxide Reductase A (MsrA) and Its Function in Ubiquitin-Like Protein Modification in Archaea. MBio 8:|
|Manley, Sharon J; Liu, Wen; Welch, Danny R (2017) The KISS1 metastasis suppressor appears to reverse the Warburg effect by shifting from glycolysis to mitochondrial beta-oxidation. J Mol Med (Berl) 95:951-963|
|Jutkowitz, Eric; MacLehose, Richard F; Gaugler, Joseph E et al. (2017) Risk Factors Associated With Cognitive, Functional, and Behavioral Trajectories of Newly Diagnosed Dementia Patients. J Gerontol A Biol Sci Med Sci 72:251-258|
|Kim, Julia; Schweizer, Tom A; Fischer, Corinne E et al. (2017) The Role of Cerebrovascular Disease on Cognitive and Functional Status and Psychosis in Severe Alzheimer's Disease. J Alzheimers Dis 55:381-389|
Showing the most recent 10 out of 257 publications